Summary
Stryker Corporation's Q2 2017 results demonstrate continued top-line growth, with consolidated net sales increasing by 6.1% year-over-year, reaching $3.01 billion. This growth was driven by a solid performance across its core segments, particularly MedSurg and Neurotechnology and Spine, with organic sales growth (excluding acquisitions and currency impacts) also showing strength. The company reported net earnings of $391 million, a modest increase from the prior year, with diluted EPS at $1.03. Financially, Stryker maintained a strong balance sheet with total assets of $21.3 billion and shareholders' equity of $10.0 billion. Operating cash flow remained robust, providing ample liquidity for operations and strategic investments. The company also highlighted its ongoing commitment to returning capital to shareholders through dividends and share repurchases, alongside strategic acquisitions like the announced deal for NOVADAQ Technologies Inc., aimed at enhancing its product portfolio.
Financial Highlights
52 data points| Revenue | $3.01B |
| Cost of Revenue | $1.02B |
| Gross Profit | $1.99B |
| R&D Expenses | $192.00M |
| SG&A Expenses | $1.13B |
| Operating Expenses | $1.49B |
| Operating Income | $502.00M |
| Net Income | $391.00M |
| EPS (Basic) | $1.04 |
| EPS (Diluted) | $1.03 |
| Shares Outstanding (Basic) | 373.90M |
| Shares Outstanding (Diluted) | 379.80M |
Key Highlights
- 1Consolidated net sales grew 6.1% to $3.01 billion for the three months ended June 29, 2017, and 11.8% to $5.97 billion for the six months ended June 29, 2017, driven by organic growth and acquisitions.
- 2Net earnings for the three months were $391 million, resulting in diluted EPS of $1.03, a slight increase from the prior year's $1.00 per share.
- 3The MedSurg segment showed significant growth, with net sales up 6.2% for the quarter, bolstered by strong performance in endoscopy and instruments.
- 4The company announced an agreement to acquire NOVADAQ Technologies Inc. for approximately $701 million, expected to close in Q3 2017, to expand its MedSurg segment offerings.
- 5Operating cash flow for the first six months of 2017 was $801 million, demonstrating strong cash generation to fund operations and investments.
- 6Stryker repurchased $230 million of its common stock and paid $318 million in dividends during the first six months of 2017, reflecting a commitment to shareholder returns.
- 7The company continues to manage significant recall charges related to the Rejuvenate and ABG II hip stems, with an estimated probable loss range of $2.04 billion to $2.29 billion.